| Filed On | Filing |
|---|---|
| 19 Dec 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On December 17, 2024, the Board appointed Mr. Myers as a member of the Compensation Committee of the Board (the "Compensation Committee"), effective immediately. |
| 11 Apr 2022 |
8-K/A: Regulation FD Disclosure
On April 8, 2022, the Company issued a press release announcing initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer,... |
Loading...